Agios Pharmaceuticals, Inc. (AGIO)
| Market Cap | 3.49B |
| Revenue (ttm) | 203.20M |
| Net Income (ttm) | -327.37M |
| Shares Out | 69.00M |
| EPS (ttm) | -4.91 |
| PE Ratio | n/a |
| Forward PE | 7.86 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $48.10 |
| Previous Close | $50.29 |
| Change ($) | -2.19 |
| Change (%) | -4.35% |
| Day's Open | 47.63 |
| Day's Range | 46.57 - 49.85 |
| Day's Volume | 593,873 |
| 52-Week Range | 27.77 - 58.93 |
Agios' (AGIO) loss meets estimates in the fourth quarter of 2020 while revenues beat the same. Sale of leukemia drug, Tibsovo, rise both sequentially as well as year over year.
– In Partnership with the Sickle Cell Community Consortium, Agios Works to Address Educational Resource Gaps Caused by COVID-19 for Students with Sickle Cell Disease –
– Strong Commercial Execution for Second Full Year of TIBSOVO ® with Fourth Quarter Net Revenue of $39.1M and $121.1M for Full Year 2020 –
CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, to...
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, t...
– 37 Percent of Patients Treated with Mitapivat Achieved ≥33% Reduction in Transfusion Burden Compared to Individual Historical Transfusion Burden Standardized to 24 Weeks (1-Sided p=0.0002) –
– Supplemental New Drug Application Planned for Submission in Q1 2021 – – Supplemental New Drug Application Planned for Submission in Q1 2021 –
– Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency in the U.S. in Q2 2021 and in the EU in Mid-2021 –
CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, to...
Agios recently sold off its oncology business to Servier for $2B ($1.8B in cash) creating a unique situation to buy a company with a strong drug development track record. With 2 drug approvals...
Investors need to pay close attention to Agios (AGIO) stock based on the movements in the options market lately.
Agios (AGIO) sells its oncology business unit to French company Servier for around $2 billion. The company plans to solely focus on developing treatments for genetically defined diseases.
Agios' newly revamped business strategy is an extreme departure from the company's original mission, but it's a great deal for shareholders.
Investors applauded the company's planned sale of its oncology portfolio.
The announcement that Agios Pharmaceuticals Inc. (NASDAQ: AGIO) will be streamlining its portfolio sent shares sharply higher early Monday.
Shares of Agios Pharmaceuticals Inc. soared 20.6% in premarket trading on Monday after the company said it is selling its oncology portfolio to Servier, a privately held French pharmaceutical ...
– Agios to Dedicate All Resources to Advancing Mitapivat as a Potential Treatment for Three Initial Hemolytic Anemias and Building on its Scientific Expertise in Cellular Metabolism and PK Act...
– Treatment with Mitapivat Induced Hemoglobin Increase of ≥1.0 g/dL in 6 of 11 (55%) Efficacy Evaluable Patients , Decreased Markers of Hemolysis, Reduced 2,3-DPG and Increased ATP –
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock?
Agios' (AGIO) phase III ACTIVATE study evaluating mitapivat for addressing PK deficiency in patients with no regular blood transfusions achieves the primary goal.
CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today ann...
CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today ann...
The FDA confers an orphan drug status on Agios' (AGIO) pyruvate kinase-R activator mitapivat for addressing sickle cell disease. Stock climbs in after-hours trading.
CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today an...
Agios' (AGIO) earnings and revenues fall shy of estimates in the third quarter. The company lifts the lower end of 2020 sales guidance for its leukemia drug Tibsovo.
Agios Pharmaceuticals' (AGIO) CEO Jackie Fouse on Q3 2020 Results - Earnings Call Transcript
Shares of Agios Pharmaceuticals (NASDAQ:AGIO) were unchanged after the company reported Q3 results.
– Third Quarter TIBSOVO® Net Revenue of $31.7 Million; Company Narrows 2020 TIBSOVO® Net U.S. Revenue Guidance to $113–115 Million –
Company to Host Virtual Investor Event and Webcast on Tuesday, December 8, 2020 at 8:00 a.m. ET Company to Host Virtual Investor Event and Webcast on Tuesday, December 8, 2020 at 8:00 a.m. ET
CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today ann...
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today an...
Agios: A Look At Mitapivat In Anaemia, Its Backup Indication
Agios (AGIO) withdraws the regulatory filing for Tibsovo in Europe, which was developed to treat relapsed/refractory acute myeloid leukemia in adult patients with a susceptible IDH1 mutation.
– Agios Continues to Advance Two Phase 3 Combination Trials of TIBSOVO ® in Newly Diagnosed AML Patients –
Agios Pharmaceuticals (AGIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
– Supplemental New Drug Application Planned f or Submission in Q1 2021 –
Andrew Hirsch to Depart Agios and Remain a Strategic Advisor through October 2020 Andrew Hirsch to Depart Agios and Remain a Strategic Advisor through October 2020
Tibsovo sales, after weakness during launch, are ramping nicely.
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock?
CAMBRIDGE, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today a...
Agios to Present at the Virtual Canaccord 40th Annual Growth Conference on Thursday, August 13, 2020
CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today a...
Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q2 2020 Results - Earnings Call Transcript
Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q2 2020 Results - Earnings Call Transcript
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 7.75% and 5.62%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the st...
– Second Quarter TIBSOVO® Net Revenue of $27.6 Million; Company Reiterates 2020 TIBSOVO® Net U.S. Revenue Guidance of $105–115 Million –
Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today ...
About AGIO
Agios Pharmaceuticals, a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutatio... [Read more...]
| Industry Biotechnology | IPO Date Jul 24, 2013 |
| CEO Jacqualyn Fouse | Employees 536 |
| Stock Exchange NASDAQ | Ticker Symbol AGIO |
Financial Performance
In 2020, AGIO's revenue was $203.20 million, an increase of 72.33% compared to the previous year's $117.91 million. Losses were -$327.37 million, -20.44% less than in 2019.
Analyst Forecasts
According to 12 analysts, the average rating for AGIO stock is "Buy." The 12-month stock price forecast is 66.10, which is an increase of 37.42% from the latest price.